Nubeqa (darolutamide) is an oral androgen receptor inhibitor used for specific types of prostate cancer. Each tablet measures about 16 mm by 8 mm, a size many consider medium-large, which often leads to questions about whether it can be cut, crushed, chewed, or dissolved.
Difficulty swallowing tablets is common, especially among older adults. Studies indicate that 10-40% of adults struggle with tablets or capsules, and up to 40% cannot swallow solid medications at all, which can affect treatment adherence.
For Nubeqa, official guidance states that the tablets are intended to be swallowed whole with food. Medical references consistently advise against crushing, chewing, splitting, or dissolving them.
This article explains why Nubeqa should not be crushed, how the medication behaves in the body, and what options you can discuss with your doctor if swallowing is a problem.
What is Nubeqa and how does it work?
Nubeqa contains darolutamide, an androgen receptor inhibitor. It is prescribed for men with the following types of prostate cancer:
-
- non-metastatic castration-resistant prostate cancer (nmCRPC)
- metastatic castration-sensitive prostate cancer (mCSPC)
- metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel
Prostate cancer cells often depend on androgens such as testosterone and dihydrotestosterone. Darolutamide attaches to androgen receptors in cancer cells and prevents these hormones from activating those receptors.
In the ARAMIS trial, men taking Nubeqa with hormone therapy had about a 31% lower risk of death compared with those on hormone therapy alone.
In the ARASENS trial, adding Nubeqa to hormone therapy and docetaxel reduced the risk of death by about 33% compared with hormone therapy and docetaxel alone. In a subgroup analysis, Nubeqa delayed progression to metastatic castration-resistant prostate cancer, reducing the risk by 65% in men under 75 and 58% in those 75 and older.
How is Nubeqa taken?
Nubeqa is supplied as film-coated tablets that contain 300 mg darolutamide each. The usual dose for adults is 600 mg twice daily with food, which is two tablets in the morning and two tablets in the evening, for a total of 1200 mg per day.
Treatment is intended to be continuous as long as it is effective and tolerated.
Nubeqa is meant to be used alongside ongoing hormone therapy. That means you’ll need to continue one of these:
-
- GnRH agonist or antagonist injections, or
- A bilateral orchiectomy (surgical removal of both testes), if you’ve already had one
Nubeqa should never be taken alone without ongoing hormone therapy.
If Nubeqa is prescribed with docetaxel chemotherapy (for mHSPC):
-
- The first docetaxel cycle should start within 6 weeks after beginning Nubeqa.
- Nubeqa continues even if docetaxel is delayed, interrupted, or stopped early.
If you forget a dose, take it as soon as you remember, as long as it’s before your next scheduled dose. Do not take two doses together to make up for the missed one.
Dose adjustments
If you experience:
-
- a severe side effect (Grade 3 or higher), or
- a side effect you feel you cannot tolerate
Your doctor may:
-
- pause Nubeqa temporarily, or
- lower your dose to 300 mg twice a day
Once the side effect improves and returns to your normal baseline, your doctor may increase your dose back to 600 mg twice a day. Doses below 300 mg twice daily aren’t recommended.
If you have a history of heart problems or seizures, your doctor may adjust your dose or monitor you more closely.
If you have severe kidney impairment (eGFR 15-29 mL/min/1.73 m²) and you’re not on dialysis, your dose will likely be 300 mg twice a day.
If you have moderate liver impairment (Child-Pugh B), your recommended dose is also 300 mg twice a day.
Can Nubeqa be crushed, split, or chewed?
Based on current labelling and independent medical references, the answer is no. Nubeqa tablets should be swallowed whole. They should not be chewed, crushed, broken, or dissolved before taking.
Why does Nubeqa need to be swallowed whole?
There are several reasons behind the instruction to avoid crushing or chewing Nubeqa.
1. Tablet design and coating
Nubeqa tablets are film-coated. The coating improves stability, protects the active ingredient during storage, and can affect how the tablet breaks apart and dissolves in the gut. Breaking or crushing a film-coated tablet can change:
-
- how quickly it breaks apart
- where along the digestive tract it starts to dissolve
- how you experience side effects
These changes can influence how the medicine is absorbed and tolerated. In addition, its entire drug development program used the intact tablet. Safety and effectiveness of crushed or cut forms simply have not been tested in clinical trials.
2. Absorption and the effect of food
Darolutamide has relatively low solubility in water and modest bioavailability when taken on an empty stomach. Studies reported an absolute bioavailability of around 30% when a single 300 mg tablet was taken while fasting.
With food, the situation changes. An analysis reported that darolutamide absorption and bioavailability improved to about 60-75% when administered with food.
For a medicine with a pronounced food effect, changing how the tablet disperses in the stomach may result in undesirable outcomes.
3. Hazardous drug and handling concerns
Nubeqa is an antineoplastic agent.
Antineoplastic drugs are considered hazardous because they can potentially cause cancer, genetic damage, or harm to fertility and pregnancy. Because of this, they fall under a category called CMR substances (carcinogenic, mutagenic, reprotoxic).
Studies have found small amounts of these drugs in the bodies of healthcare workers who handle them, such as pharmacists and nurses. This means exposure can happen just from working around these medications.
The film coating helps limit direct contact with the drug.
Crushing the tablet at home removes that protective barrier and would create powder that could be inhaled or come into contact with the skin. That would increase exposure for caregivers, family members, children, or pregnant visitors in the household.
Tips for swallowing Nubeqa tablets
If you find Nubeqa hard to swallow, it is important to tell your doctor. Quietly suffering through each dose can reduce adherence and affect treatment outcome.
Practical strategies you can discuss with your clinician include:
-
- Taking Nubeqa with a meal that has enough moisture to help the tablet slide down, such as yogurt or pudding, while still swallowing the tablet intact.
-
- Using a full glass of water.
-
- Trying pill swallowing aids such as gel caps, coating cups, or special bottles that guide the tablet down the throat.
Some oncology centers can refer patients to speech-language pathologists who teach structured swallowing exercises and techniques.
Here’s a YouTube video demonstrating swallowing exercises and techniques led by a speech and language therapist:
If swallowing difficulty persists, your oncologist might:
-
- Review other medications to see whether any are increasing dry mouth or affecting swallowing reflexes.
-
- Look for treatable causes such as esophageal strictures, reflux disease, or neurological problems.
-
- Consider alternative cancer treatments if safe options exist in your situation.
Switching therapy is not always possible and can have trade-offs. For example, other oral androgen receptor inhibitors, such as enzalutamide (Xtandi) or apalutamide (Erleada), also come as solid oral dosage forms that are not routinely crushed in practice.
Your oncologist will weigh your disease stage, other health conditions, and personal preferences when discussing any change in therapy.
Bottom line
Nubeqa improves survival in several types of prostate cancer and is taken as 600 mg twice daily with food alongside ongoing hormone therapy. Because the tablets are film-coated, designed for specific absorption, and classified as hazardous, they must be swallowed whole and should not be crushed or split.
For those who struggle with swallowing, practical techniques and clinical support are available, and any concerns should be discussed with an oncology team to keep treatment safe and effective.
Frequently Asked Questions
Sources
VandenBerg, C. J., Adams, A., Bockrath, R., Kim, S., Rodriguez, G., Fawcett, A., & Jhaveri, R. (2023). Hard to Swallow: A review of interventions to improve swallowing solid medication. Hospital Pediatrics, 13(5), e123–e132. https://doi.org/10.1542/hpeds.2021-006497
Dosing Information | NUBEQA® (darolutamide) | HCP. (n.d.). Nubeqa HCP US FTP Label. https://www.nubeqahcp.com/dosing
Cancer Resources from OncoLink, Treatment, Research, Coping, Clinical Trials, Prevention. (n.d.). Darolutamide (Nubeqa®) | OncoLink. University of Pennsylvania – OncoLink. https://www.oncolink.org/cancer-treatment/oncolink-rx/darolutamide-nubeqa-R
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Berre, M. L., Petrenciuc, O., Snapir, A., Sarapohja, T., & Smith, M. R. (2020). Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. New England Journal of Medicine, 383(11), 1040–1049. https://doi.org/10.1056/nejmoa2001342
Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B., Montesa-Pino, Á., Ye, D., Parnis, F., Cruz, F., Tammela, T. L., Suzuki, H., Utriainen, T., Fu, C., Uemura, M., Méndez-Vidal, M. J., . . . Tombal, B. (2022). Darolutamide and survival in Metastatic, Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 386(12), 1132–1142. https://doi.org/10.1056/nejmoa2119115d
Carles, J., Tombal, B., Hussain, M., Saad, F., Fizazi, K., Pino, Á. M., Méndez-Vidal, M. J., Rodriguez-Vida, A., Castellano, D., Borrega, P., Adorjan, P., Moretones, C., Dissanayake, M., & Smith, M. R. (2025). Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial. European Urology Oncology. https://doi.org/10.1016/j.euo.2025.10.001
Podgoršek, E., Mehra, N., Van Oort, I. M., Somford, D. M., Boerrigter, E., & Van Erp, N. P. (2023). Clinical pharmacokinetics and pharmacodynamics of the next generation Androgen Receptor Inhibitor—Darolutamide. Clinical Pharmacokinetics, 62(8), 1049–1061. https://doi.org/10.1007/s40262-023-01268-w
Zurth, C., Nykänen, P., Wilkinson, G., Taavitsainen, P., Vuorela, A., Huang, F., Reschke, S., & Koskinen, M. (2021). Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment. Clinical Pharmacokinetics, 61(4), 565–575. https://doi.org/10.1007/s40262-021-01078-y
Portilha-Cunha, M. F., Norton, P., Alves, A., Ribeiro, A. R., Silva, A. M., & Santos, M. S. (2024). Antineoplastic drugs in healthcare settings: Occupational exposure and risk graduation. Emerging Contaminants, 11(1), 100418. https://doi.org/10.1016/j.emcon.2024.100418
